R&D News | pharmaphorum

News

Drug/software combination improves blood pressure control

The combination of drugs for hypertension and software to personalise dosing to an individual patient has been shown to deliver improved blood pressure control and adheren

R&D

Synlogic shuts down after PKU drug fails phase 3 trial

Shares in Synlogic have halved in value after the company reported that a phase 3 trial of its main pipeline drug for rare metabolic disorder phenylketonuria (PKU) failed

News

Kyverna prices its IPO, seeking $319m for its cell therapies

Kyverna Therapeutics has announced the pricing of its initial public offering, and in another sign of the improving biotech financing environment has raised its target pro

News

Could the next Alzheimer’s drug discovery be… Viagra?

Epidemiological studies can often throw out intriguing and sometimes erroneous correlations between a variable and a disease, but UK scientists say a finding that Alzheime

News

Gilead drops CD47 drug magrolimab for blood cancers

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical t

News

Jazz buys KRAS inhibitors from Redx in $880m deal

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,

Drug/software combination improves blood pressure control

Synlogic shuts down after PKU drug fails phase 3 trial

Kyverna prices its IPO, seeking $319m for its cell therapies

Could the next Alzheimer’s drug discovery be… Viagra?

Gilead drops CD47 drug magrolimab for blood cancers

Jazz buys KRAS inhibitors from Redx in $880m deal

Oral Wegovy bolsters Novo in Q3

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks